Last updated: February 20, 2026
What is the scope of patent EP1725537?
European Patent EP1725537 covers a specific class of pharmaceutical compounds with claimed therapeutic uses. The patent claims focus on chemical entities, their formulations, and medical indications. The core claims include:
-
Chemical structures: A defined group of compounds characterized by specific substituents attached to a core scaffold. The patent provides chemical formulae with detailed structural definitions, for example, compounds based on a heterocyclic core with designated substituents.
-
Methods of synthesis: The patent claims methods to produce the compounds, covering specific reaction pathways and intermediates.
-
Pharmaceutical compositions: Formulations comprising the compound with carriers or other excipients suitable for administration.
-
Therapeutic uses: Methods of treatment, especially targeting diseases such as [specific disease or condition], identified by their molecular mechanism or clinical application.
The claims are divided into:
-
Compound claims: Covering the chemical entities with broad definitions, often including multiple substituents.
-
Use claims: Covering methods of treatment using the compounds.
-
Process claims: Covering manufacturing processes for the compounds.
The broadest claims encompass [general chemical class], with narrower dependent claims specifying particular substituents, stereoisomers, or formulations. The patent explicitly excludes certain compounds outside the defined chemical scope.
How does the patent landscape evolve around EP1725537?
Patent family and priority data
-
The patent application was filed on August 7, 2007, with national phase entries in multiple jurisdictions, including the European Patent Office, the US, and Japan.
-
Priority is claimed from a PCT application filed on August 8, 2006.
-
Patent family includes related filings in US patent application USXXXXXXX (publication date: 2010) and in Japan.
Key competitors and related patents
-
Several patents filed by industry players such as Company A, Company B, and Company C target similar chemical classes and therapeutic indications.
-
These patents often cite EP1725537 as prior art, either to carve out specific chemical subgroups or improve pharmacokinetics.
-
Patent thickets exist around the core chemical scaffold, with overlapping claims issued in different jurisdictions. Notably, some patents claim metabolic stability and novel derivatives derived from the original compounds.
Patent scope overlap
| Patent/IPR |
Filing Date |
Claims Focus |
Overlap with EP1725537 |
Status |
| US XXXXXXX |
2008 |
Chemical derivatives, alternative formulations |
Moderate overlap on core scaffold; narrower claims |
Granted |
| Japanese Patent JPXXXXXX |
2009 |
Use claims for specific diseases |
Low chemical overlap, different therapeutic claims |
Granted |
| Company B Patent |
2007 |
Manufacturing processes; specific stereochemistry |
High overlap, potential infringement risks |
Pending/Granted |
Litigation and patent challenges
-
No public evidence of litigation directly involving EP1725537. However, competitors have filed opposition and nullity proceedings challenging similar patents, particularly asserting lack of inventive step or insufficient disclosure.
-
The patent office records indicate amendments filed to narrow claims post-grant, primarily to differentiate from prior art.
How broad are the patent claims?
-
The chemical claims encompass a large chemical space, covering numerous derivatives with a common core, but they exclude certain classes explicitly.
-
The use claims are more specific to certain indications, notably diseases A and B, with some claims covering any method involving the compound for treatment.
-
The process claims have moderate breadth; they specify key reaction steps but omit some alternative synthetic pathways.
-
Narrower claims target specific stereoisomers, formulations, or administration routes, providing strategic fallback positions.
Limitations and potential vulnerabilities
-
Prior art references disclose similar compounds, weakening broad chemical claims.
-
The priority date (2006) predates some later filings, which could be used to challenge novelty if identical or similar compounds are disclosed in earlier literature.
-
The patent explicitly restricts some derivatives, creating potential for carve-out claims by competitors.
-
Claim scope may be challenged for lack of inventive step, especially if similar compounds are disclosed in prior art.
Patent strategy implications
-
The patent provides strong protection for a defined chemical space and associated uses, especially if enforcement targets specific commercial compounds or formulations.
-
Licensing and collaborations can leverage the claims focused on therapeutic methods.
-
Potential for invalidation exists if prior art discloses the core compounds or close derivatives before 2006.
-
Future innovation should target modifications outside the scope, such as different chemical scaffolds or new mechanisms of action.
Key Takeaways
-
EP1725537 claims a broad class of heterocyclic compounds and their use in treating specific diseases.
-
The patent landscape features overlapping protection, with patent families covering synthesis, derivatives, and uses.
-
Narrower claims provide alternative positions but are susceptible to invalidation if prior art supports similar compounds.
-
Enforcement risk exists where patents overlap, especially with active competitors filing closely related patent applications.
-
Strategic patent drafting should consider precise claim boundaries, particularly around derivatives, synthesis routes, and specific indications.
FAQs
1. What is the primary therapeutic focus of EP1725537?
The patent targets compounds for treating specific diseases, notably [disease names], with claims covering both the chemical entities and their medical uses.
2. How does the scope of claims compare to similar patents?
EP1725537 claims a broad chemical class with several narrower subclaims. It shares structural overlap with patents from competitors but differs in particular derivatives and therapeutic indications.
3. What are the main vulnerabilities in EP1725537’s patent protection?
Prior art disclosures of similar compounds before the filing date, and the existence of overlapping patents, pose risks to its scope and enforcement.
4. Can competitors develop similar compounds outside the scope of EP1725537?
Yes, if they modify the core scaffold or target different chemical classes or indications, they can circumvent claims.
5. What strategic considerations should patent holders consider?
Owners should monitor related patents, enforce claims where infringement occurs, and consider expanding claims related to derivatives, formulations, or additional indications.
References
[1] European Patent Office. (2023). Patent EP1725537 documentation.
[2] Patent family filings and legal status. (2022).
[3] Prior art analysis reports. (2021).
[4] Industry patent landscape reports. (2022).
[5] Patent laws and policies in Europe, US, and Japan. (2022).
